Similar articles

• No difference in plasma fibrinogen levels between CAPD patients taking atorvastatin and simvastatin.

  Singhal MK, Bhaskaran S, Szabo T, La Rosa R. Singhal MK, et al. Perit Dial Int. 1999 Jan-Feb;19(1):89-91. Perit Dial Int. 1999. PMID: 10201354 No abstract available.
• Statins for patients with type 2 diabetes.

  Auer J, Berent R, Weber T, Eber B. Auer J, et al. Lancet. 2004 Nov 27-Dec 3;364(9449):1933-4. doi: 10.1016/S0140-6736(04)17464-3. Lancet. 2004. PMID: 15566997 No abstract available.
• Targeting HDL-cholesterol to reduce residual cardiovascular risk.

  Iacob AO, Choudhury RP. Iacob AO, et al. Curr Opin Lipidol. 2012 Apr;23(2):172-4. doi: 10.1097/MOL.0b013e32835135bd. Curr Opin Lipidol. 2012. PMID: 22418577 Review. No abstract available.
• [Effectiveness of atorvastatin compared to other statins of usual clinical practice in primary care].

  Sicras Mainar A, Navarro Artieda R, Fernández de Bobadilla J, Checa JC. Sicras Mainar A, et al. Med Clin (Barc). 2006 Oct 14;127(14):555-6. doi: 10.1157/13093726. Med Clin (Barc). 2006. PMID: 17145005 Spanish. No abstract available.
• Atorvastatin calcium: an addition to HMG-CoA reductase inhibitors.

  Chong PH, Seeger JD. Chong PH, et al. Pharmacotherapy. 1997 Nov-Dec;17(6):1157-77. Pharmacotherapy. 1997. PMID: 9399600 Review.